<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nierengarten, Mary Beth</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Baber, Usman</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PROMETHEUS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-06-25 12:08:30</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4-5</style></pages><abstract><style  face="normal" font="default" size="100%">The retrospective PROMETHEUS study demonstrated that patients with an acute coronary syndrome who underwent percutaneous coronary intervention were more likely to be treated by their physicians with prasugrel as opposed to clopidogrel if they were younger and had a lower risk factor burden. The adjusted rate of ischemic events and bleeding risk is similar with prasugrel and clopidogrel.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>